Ancora Advisors’s Provectus Biopharmaceuticals PVCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PVCT
AW
Ancora Advisors's PVCT Position: Q3 2023 in Review
Ancora Advisors sold out of Provectus Biopharmaceuticals (PVCT) in Q3 2023, closing a stake of 7,650 shares — an estimated $865 sold.
Ancora Advisors first reported a position in PVCT in Q1 2021 and held it in 10 quarters. The position peaked at $1.26K in Q1 2023. 6 funds tracked by Wall St. Rank hold PVCT as of Q3 2023.
- Ancora Advisors reported no remaining Provectus Biopharmaceuticals position as of Q3 2023 after selling out during the quarter.
- Ancora Advisors sold 7,650 Provectus Biopharmaceuticals shares in Q3 2023, an estimated $865.
- Ancora Advisors first reported a position in Provectus Biopharmaceuticals in Q1 2021 and held it in 10 quarters.
- Ancora Advisors's Provectus Biopharmaceuticals position peaked at $1.26K in Q1 2023.
- 6 funds tracked by Wall St. Rank held Provectus Biopharmaceuticals as of Q3 2023.
Based on Ancora Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.